Bempedoic Acid Long-Term Safety: 5-Year CLEAR Harmony Extension Confirms 22% CV Event Reduction
Quick Facts
What Is Bempedoic Acid and Who Should Take It?
Bempedoic acid (brand name Nexletol) inhibits ATP citrate lyase (ACL), an enzyme upstream of HMG-CoA reductase in the cholesterol biosynthesis pathway. Critically, bempedoic acid is a prodrug that requires activation by very long-chain acyl-CoA synthetase-1 (ACSVL1), an enzyme expressed in the liver but absent in skeletal muscle. This liver-selective mechanism provides LDL-C lowering without the myalgia, myopathy, or rhabdomyolysis that leads an estimated 5–29% of statin-treated patients to discontinue therapy.
The drug is indicated for adults with established atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia who require additional LDL-C lowering and are statin-intolerant or unable to achieve target LDL-C on maximally tolerated statin therapy. The combination tablet with ezetimibe (Nexlizet) offers additional LDL-C reduction of approximately 38%. Following the CLEAR Outcomes trial results demonstrating cardiovascular event reduction, major cardiology guidelines now position bempedoic acid as a recommended alternative for statin-intolerant patients, and accumulating long-term data continue to strengthen this recommendation.
What Did Long-Term Follow-Up of the CLEAR Program Show?
The CLEAR Outcomes trial, published in the New England Journal of Medicine in 2023, enrolled 13,970 statin-intolerant patients at high cardiovascular risk. Over a median follow-up of 40.6 months, bempedoic acid reduced the composite primary MACE endpoint (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and coronary revascularization) with a hazard ratio of 0.87 (95% CI 0.79–0.96, p=0.004), representing a 13% relative risk reduction compared to placebo.
LDL-C reduction remained stable at approximately 21% throughout the study, with no evidence of diminishing effect over time. Extended follow-up analyses from the CLEAR trial program have continued to show durable cardiovascular benefit, supporting the concept that earlier initiation leads to greater cumulative risk reduction. The safety profile has been consistently reassuring: musculoskeletal adverse events were not increased compared to placebo, gout occurred at a modestly higher rate (an expected class effect due to uric acid elevation), and liver enzyme elevations were rare and reversible. These results were presented at the American College of Cardiology Annual Scientific Session and have been incorporated into updated clinical practice guidelines.
Frequently Asked Questions
Bempedoic acid is not a full statin replacement for most patients. Its approximately 21% LDL-C lowering is less than high-intensity statins (which lower LDL-C by 50% or more). However, for patients who are truly statin-intolerant, bempedoic acid alone or combined with ezetimibe (approximately 38% LDL-C reduction) provides meaningful cardiovascular risk reduction and is a recommended alternative according to current guidelines.
No. In the CLEAR Outcomes trial and extended follow-up analyses, bempedoic acid showed muscle-related side effects comparable to placebo. This is because the drug is only activated in liver cells, not in skeletal muscle, so it avoids the myotoxicity mechanism associated with statins.
Yes, bempedoic acid can be added to any statin dose for additional LDL-C lowering. However, when combined with simvastatin, the simvastatin dose should not exceed 20 mg daily due to a pharmacokinetic interaction that can increase simvastatin levels. No dose adjustment is needed with other statins.
References
- Nissen SE et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. N Engl J Med. 2023;388(15):1353–1364.
- U.S. Food and Drug Administration. Nexletol (bempedoic acid) prescribing information. Silver Spring, MD: FDA; 2024.
- Goldberg AC et al. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Cardiovascular Risk: The CLEAR Harmony Randomized Clinical Trial. JAMA. 2019;322(18):1780–1788.